New weekly shot could help control blood sugar in type 2 diabetes
NCT ID NCT05680155
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new drug called ecnoglutide (XW003) in 211 adults with type 2 diabetes that was not well controlled by diet and exercise alone. Participants received either the drug or a placebo as a weekly injection for several weeks. The main goal was to see if the drug could lower blood sugar levels (HbA1c) safely and effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ecnoglutide (XW003), a once-weekly injection
- What this could lead to
- If it works, this could offer a new once-weekly injection to help people with type 2 diabetes lower blood sugar and manage their condition.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. It may not show a meaningful benefit over placebo, and side effects like nausea or hypoglycemia are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections